The results from pooled analysis of VCUART clinical trials suggest that IL-1 blockade with anakinra for 14 days in STEMI patients can reduce the incidence of new onset HF or HF hospitalizations within 1 year after STEMI surgery [45]. This evidence concerns the gene IL1A and hydrops fetalis.